Bibliography
- TOPOL EJ, EASTON D, HARRINGTON RA et al.: Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Blockade of the Glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion Trial Investigators. Circulation (2003) 108:399–406.
- ••A landmark trial that evaluated the safetyand efficacy of the oral platelet GP IIWITIa antagonist lotrafiban in patients with coronary and cerebrovascular disease. Results of the BRAVO study support the disappointing results of the earlier studies, which revealed that the use of oral GP IIWITIa inhibitors, although theoretically appealing, was associated with an unacceptable increased mortality and failed to demonstrate any meaningful improvement in clinical outcomes.
- SALAM AM, SUWAIDI JA: Platelet glycoprotein IIb/IIIa antagonists in clinical trials for the treatment of coronary artery disease. Expert Opin. Investig. Drugs (2002) 11(11):1645–1658.
- •An excellent review of clinical trials of platelet GP II13/IIIa inhibitors.
- O'NEIL WW, SERRUYS P, KNUDTSON M et al.: Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization: Excite Trial Investigators: Evaluation of Oral Xemilofiban in Controlling Thrombotic Events. N Engl. I Med. (2000) 342:1316–1324.
- CANNON CP, MCCABE CH, WILCOX RG et al.: Oral glycoprotein IIb/ IIIa Inhibition with orofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation (2000) 102(2):149–156.
- SYMPHONY INVESTIGATORS: Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomized trial: Sibrafiban Versus Aspirin to Yield Maximum Protection From Ischemic Heart Events Post-Acute Coronary Syndromes. Lancet (2000) 355:337–345.
- SECOND SYMPHONY INVESTIGATORS: Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes. Circulation (2001) 103:1727–1733.
- CHEW DP, BHATT DL, SAPP S, TOPOL EJ: Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists. A meta-analysis of Phase III multicenter randomized trials. Circulation (2001) 103:201–206.
- ••Meta-analysis of major randomised clinicaltrials for oral GP IIbaila antagonists.
- HARRINGTON RA, ARMSTRONG PW, GRAFFAGNINO C et al.: Dose-finding, safety, and tolerability of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease. The Anti-Platelet Useful Dose (APLAUD) Study Investigators. Circulation (2000) 102:728–735.
- ADDERLEY SR, FITZGERALD DJ: Glycoprotein IIb/IIIa antagonists induce apoptosis in rat cardiomyocytes by caspase-3 activation. Biol. Chem. (2000) 275:5760–5766.